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Objectives. We examined the effectiveness of the microbubbles
of an echo contrast agent, dodecafluoropentane (DDFP) emulsion,
to enhance low frequency ultrasound clot disruption in vitro and
in vivo.
Background. Ultrasound is reported to facilitate clot dissolu-
tion, and microbubbles could theoretically enhance ultrasound
clot dissolution by augmenting cavitational effects.
Methods. In vitro studies: The disruption rate of fresh human
clots by ultrasound (24 kHz, 2.9 W/cm2) was examined in saline
and DDFP emulsion. In vivo studies: Using a rabbit iliofemoral
thrombotic occlusion model, recanalization rate and histopatho-
logic findings were compared among groups treated with DDFP
emulsion alone, transcutaneous ultrasound (20 kHz, 1.5 W/cm2)
alone and with DDFP emulsion and ultrasound combined.
Results. The ultrasound clot disruption rate was significantly
(p < 0.01) increased, from 72 6 18% (mean 6 SD) in saline to
98 6 4% in DDFP emulsion in 3 min in vitro. No vessel was
recanalized by DDFP emulsion alone (0%), and only a single
artery was patent after ultrasound treatment alone (9%). In
contrast, 82% of iliofemoral arteries were angiographically re-
canalized after ultrasound treatment with DDFP emulsion. His-
tologically, the patent arteries had only minimal focal mural
thrombus, with no evidence of vessel wall damage. However,
substantial damage was observed in rabbit dermis and subcuta-
neous tissue.
Conclusions. 1) DDFP emulsion, an echo contrast agent, sig-
nificantly enhances the clot-disrupting effect of low frequency
ultrasound in vitro and in an in vivo rabbit iliofemoral occlusion
model. 2) This simple combination therapy has potential for
clinical application in patients with thrombotic arterial occlu-
sions.
(J Am Coll Cardiol 1997;30:561–8)
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Thrombolytic therapy is the most widely used technique to
recanalize the abruptly occluded coronary artery in patients
with myocardial infarction. Although intravenous thrombolysis
reduces mortality (1–5) and preserves left ventricular function
(3,6,7), thrombolytic agents have several unresolved problems:
1) The initial recanalization rate is ;70%; 2) Thrombolysis in
Myocardial Infarction (TIMI) grade 3 flow is achieved in
,60% of patients; 3) intermittent patency and reocclusion of
the recanalized artery are not uncommon (8); 4) hemorrhagic
complications are more frequent at higher dosages and in
older patients; and 5) substantial time is necessary to achieve
successful recanalization. Therefore, the development of a new
noninvasive technique that can rapidly dissolve blood clots
without an incremental hemorrhagic risk would be very useful.
Application of ultrasound energy for clot dissolution has
been investigated for .20 years. Catheter-delivered low fre-
quency (17.5 to 27.5 kHz) ultrasound had succeeded in dis-
solving clots in vitro (9–15), in vivo in animal models (12,14,16)
and in patients (16,17) without thrombolytic agents. However,
like other catheter-based interventional techniques, this tech-
nique is limited by the time delay to intervention and by other
technical, financial and logistic factors. Transcutaneous expo-
sure of ultrasound energy has been reported to enhance the
effect of thrombolytic agents in vitro (18–27) and in vivo in
animal models (19,28–30). However, relatively few studies
have examined the clot-disrupting effects of transcutaneous
ultrasound energy without thrombolytic agents (26,27,31).
The most likely mechanism of low frequency ultrasound
clot disruption without the concomitant use of a thrombolytic
agent is reported to be acoustic cavitation (unstable or tran-
sient cavitation), which is the generation, growth and disrup-
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tion of microbubbles (9,10,13–15,19,26,27,30–33). When the
bubbles collapse, a very high local pressure charge is produced.
Another possible mechanism is precavitation (stable cavita-
tion), which is the oscillation or vibration of microbubbles
(20,21,29). Precavitation itself produces large shock waves and
also causes microstreaming of liquids. Recently, various
transpulmonary echo contrast agents, which are basically mi-
crobubbles, have been developed to opacify the left ventricular
cavity and even to illustrate myocardial perfusion by intrave-
nous injection (34–38). Tachibana and Tachibana (39) dem-
onstrated that sonicated human serum albumin microbubbles
enhanced in vitro thrombolysis with combined application of
urokinase and ultrasound (170 kHz). Porter et al. (27) re-
ported the efficacy of perfluorocarbon-exposed sonicated dex-
trose albumin in enhancing ultrasound clot disruption in vitro.
Therefore, we hypothesized that the addition of micro-
bubbles, which have been used as transpulmonary echo con-
trast agents, might enhance lower frequency ultrasound clot
disruption by increasing the number of microbubbles and the
energy produced by collapse or oscillation of microbubbles, or
both.
Accordingly the aims of this study are 1) to examine the
effect of the microbubbles of a transpulmonary echo contrast
agent on ultrasound clot disruption in vitro, and 2) to investi-
gate the enhancing effect of microbubbles on the in vivo
recanalization rate of thrombotically occluded rabbit ilio-
femoral arteries by transcutaneous ultrasound exposure.
Methods
In vitro study. Clot preparation. Whole blood was obtained
by antecubital venipuncture from three healthy volunteers in
the morning after a 12-h fast. The blood was allowed to
coagulate in a glass test tube at room temperature for 2 to 3 h.
After serum was aspirated, the clots were cut into pieces 417 to
543 mg in weight. Each clot was weighed on a precision scale
(Mettler PN 323) and placed in a plastic cassette (33 3 28 3
6 mm) with 118 rectangular windows (5 3 1 mm), usually used
for processing pathologic specimens, to protect each clot from
the potential thrombus-disrupting effects of floating under
ultrasound exposure and to keep the clot at the same site in the
ultrasound field.
In vitro ultrasound system. The in vitro ultrasound system
consists of an ultrasound generator (ENI generator EGR-700,
Blackstone Ultrasonics) and a transducer beaker of 304 stain-
less steel, with a capacity of 600 ml (84-mm diameter, 109-mm
height, 0.8-mm wall thickness). The transducer is located on
the outside bottom center of the beaker. This system operates
in continuous mode at a power output of 50 W with a
frequency of 24.8 kHz. The calculated acoustic intensity was
2.93 W/cm2, and the ultrasound pressure level was 42.7 psi.
The ultrasound field produces plane waves in the liquid, and
no dissipation of ultrasound energy was expected at the site of
thrombi, which were located #4 mm above the transducer.
Echo contrast agent. An echo contrast agent, EchoGen
(Sonus Pharmaceuticals, Inc.), which is under clinical investi-
gation, was used to examine its enhancing effect of ultrasound
clot disruption. EchoGen is a 2% dodecafluoropentane
(DDFP) emulsion that makes a phase shift at body tempera-
ture from liquid to microbubbles (34,35,37,38). DDFP is
usually injected intravenously to opacify the left side of the
heart, is mainly excreted from the lung, and it has the following
pharmacokinetics in blood (one-compartment model): half-life
in beta-phase 2.45 6 0.26 min (mean 6 SD), area under curve
19.3 6 2.4 ppmzmin; and total clearance 3,885 6 465 liters/
min/per kg (unpublished data, 1995). Three ml of DDFP were
diluted with 1,000 ml of warmed saline (0.3 vol%), and
appropriate amounts of this solution were used to fill the
transducer beaker. Assuming that the blood pool of the
average human is ;8% of body weight and blood plasma
occupies 50% to 60% of total blood volume, the simulated
dosage in humans was calculated to be 0.12 to 0.14 ml/kg.
DDFP was used in an animal model in a wide range of doses
from 0.01 to 1.0 ml/kg, and the dosages used in human clinical
trials were 0.01 to 0.1 ml/kg (unpublished data, 1995).
Clot disruption protocol. Four groups of clots, each of which
consisted of eight clots, were examined. The first two groups of
clots, each of which was in a plastic cassette, were placed in
degassed saline or DDFP and incubated at 37°C for 3 min
without exposure to ultrasound. The second two groups of
clots, each of which was in a plastic cassette, were also placed
in each solution warmed to 35°C, respectively, and exposed to
24.8 kHz of ultrasound for 3 min. The temperature of the
solution exposed to ultrasound increased up to 37° to 38°C
after 3 min. After external ultrasound exposure, each clot was
weighed on the specimen scale again. Absolute reduction and
percent reduction in clot weight after each procedure were
calculated as the extent of clot disruption.
Measurement of particulate size. The solution containing the
dissolved clot was collected after each procedure, and a flow
cytometric analyzer (Technicon H-I, Instruments Corp.) was
used to measure the size of particulate debris after ultrasound
clot disruption. The details of the method used in our labora-
tory have been previously reported (14). Particulate size was
calculated using the formula V 5 pd3/6, where d 5 diameter;
and V 5 volume; and assuming that the particulate can be
approximately spherical. The validity of this spherical approx-
imation and the implication of other shapes have previously
been reported by our laboratory (12). DDFP droplets were not
included in the particulate size measurement because at room
temperature they are too small (;0.3 to 0.4 mm in diameter) to
be detected by this technique.
In vivo study. Induction of thrombotic occlusion. American
Physiological Society Guidelines for Animal Research were
followed, which conform to the “Position of the American
Abbreviations and Acronyms
DDFP 5 dodecafluoropentane
TIMI 5 Thrombolysis in Myocardial Infarction
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Heart Association on Research Animal Use” adopted by the
Association in November 1984. Nineteen adult New Zealand
White rabbits weighing 3.4 to 5.1 kg were anesthetized and
maintained with ketamine (20 mg/kg body weight) and xylazine
(3.0 mg/kg) intravenously. A 5F arterial sheath was inserted by
cutdown surgical technique into the right carotid artery. After
sheath insertion, 1 rabbit died of aortic dissection, and 18
rabbits (4.2 6 0.5 kg) were included in this study.
Thrombotic occlusion in the iliofemoral artery was induced
by electricity, as previously described by our laboratory (14). A
3.5F coronary Tracker catheter over a 0.014-in. coronary guide
wire was inserted through the carotid arterial sheath into the
iliofemoral artery. The guide wire was advanced to protrude
1 cm beyond the tip of the Tracker catheter. Subsequently, a
3-V battery was connected with its positive end to the wire and
with the negative end to the rabbit’s skin. Electrical interfer-
ence on the electrocardiographic monitor indicated that an
electric current was established. Complete occlusion of the
iliofemoral artery was confirmed by angiography, which was
performed every 30 min after the initiation of electrical
stimulation. Each angiogram was acquired just after intraarte-
rial injection of 100 mg of nitroglycerin to exclude possible
arterial spasm. Accordingly, the age of the in vivo clots after
complete arterial occlusion was ,30 min.
Experimental protocol 1: ultrasound alone versus ultrasound
and DDFP combined. Twenty-four iliofemoral arteries of 12
rabbits were used to compare the in vivo enhancing effects of
DDFP on ultrasound clot dissolution. This experiment was
performed in two randomly allocated consecutive phases: one
phase for transcutaneous ultrasound alone on an occluded
iliofemoral artery and the other for both transcutaneous
ultrasound and DDFP administration on the contralateral side.
One rabbit died after completion of the phase for transcuta-
neous ultrasound alone; therefore, 22 thrombotically occluded
iliofemoral arteries of 11 rabbits (mean weight 4.0 6 0.5 kg,
range 3.4 to 5.1) were included in this protocol.
At the phase for combined treatment with transcutaneous
ultrasound and DDFP, ultrasound was applied transcutane-
ously over the area of the thrombotically occluded artery
through ultrasound gel after injection of 2 ml (initial dosage)
of DDFP (nondiluted EchoGen) at room temperature into the
iliac artery on the occluded side. The arterial occlusion site was
identified by a metallic marker placed on the skin. It was
placed above the occlusion site at the time of the angiogram
that documented the induction of the arterial occlusion. An-
giography was performed after 10 min of ultrasound exposure.
If TIMI grade 3 flow was achieved, transcutaneous ultrasound
treatment was terminated. If TIMI grade 0 to 2 arterial flow
remained, transcutaneous ultrasound exposure was continued
for 10 more min after intraarterial injection of 1 ml (additional
dosage) of DDFP, and angiography was performed. This
procedure was repeated maximally four times or until TIMI
grade 3 flow was achieved. Therefore, at maximum, the total
dosage of DDFP used was 5 ml, and the total time period of
transcutaneous ultrasound exposure was 40 min with a 60-min
postocclusion period that included 20 min of intermissions
(5 min 3 4) for DDFP emulsion injection and angiography. To
prevent thermal damage to the skin by ultrasound, ultrasound
gel placed between the transducer and the skin was cooled by
ice, and during 5 min of intermission, the transducer was
cooled by ice and the skin was cooled by cold water or cooled
gel.
At the phase for transcutaneous ultrasound treatment alone
on the contralateral side, the same procedure was performed,
except for the intraarterial injection of DDFP. If the phase for
transcutaneous ultrasound alone was initially allocated, no part
of the thrombus occluding the artery was exposed to DDFP.
Even when this phase was accomplished after the combined
treatment with transcutaneous ultrasound and DDFP, previ-
ously injected DDFP was considered to have disappeared from
the cardiovascular system of the rabbit because its in vivo
half-life is ;2 to 3 min, and 90 to 180 min was required to
induce a new iliofemoral thrombotic occlusion on the con-
tralateral side. At 15 and 30 min after the termination of each
phase, angiography was repeated to evaluate the patency and
TIMI grade flow of the artery exposed to transcutaneous
ultrasound.
In four rabbits, to examine the pure thermal effect of
ultrasound, tissue temperatures of the skin at which the
ultrasound probe was attached and the soft tissue around the
iliofemoral artery were measured with a needle thermal probe
(Omega Engineering, Inc.) without any cooling procedures
before and 5 and 10 min after ultrasound exposure.
Experimental protocol 2: DDFP alone versus ultrasound and
DDFP combined. To compare the direct thrombolytic and
combined effects of DDFP with transcutaneous ultrasound, 12
iliofemoral arteries of six rabbits (mean weight 4.4 6 0.5 kg,
range 3.8 to 5.0) were used in this protocol. This experiment
was also performed in two randomly allocated consecutive
phases: one phase for injection of DDFP alone into a throm-
botically occluded iliofemoral artery and the other for both
transcutaneous ultrasound and DDFP administration on the
contralateral side.
At the phase for combined treatment with transcutaneous
ultrasound and DDFP, the procedure was exactly the same as
that for experimental protocol 1. At the phase for DDFP
administration alone, the occluded artery was not exposed to
ultrasound, and DDFP was injected into the iliac artery
proximal to the occluded site, as performed in the phase for
combined treatment.
Transcutaneous ultrasound system. Transcutaneous ultra-
sound was exposed from a 0.5-in sonicating horn with a flat tip
that was connected to a converter and a generator (Heat
Systems—Ultrasonics, Inc.). This system operates in con-
tinuous mode at a frequency of 20 kHz and an intensity of
1.5 W/cm2.
Angiographic procedure. Manual injection of 1 to 2 ml of
Omnipaque (Sanofi Winthrop Pharmaceuticals) was used for
each angiogram. All studies were recorded with both 35-mm
cine film at 30 frames/s and digital acquisition (Advantex,
DXC, GE Medical System) with a posteroanterior projection.
The angiograms were analyzed by a consensus of four investi-
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gators (T.N., H.L., H.B., R.J.S.) for the presence or absence of
occlusion, TIMI grade flow, vessel spasm and distal or side
branch embolization.
Pathologic studies. After the experiment, 11 rabbits in
protocol 1 were euthanized by injecting 3 to 4 ml of sodi-
um pentobarbital intravenously. The iliofemoral arteries,
ultrasound-exposed skin and soft tissues were excised, exam-
ined grossly and then fixed in 10% neutral buffered formalin
for 24 to 72 h. The iliofemoral arteries were then cut trans-
versely every 2 to 3 mm for the length of the vessel. Samples
were dehydrated in graded alcohol, cleared in Hemo-De and
embedded in paraffin. Sections 4 to 5 mm thick were cut and
mounted on glass slides and stained with hematoxylin and eosin.
Statistical analysis. Results are given as mean value 6 SD.
In the in vitro study, percent reductions of clot weight after
each procedure were compared using the unpaired Student t
test. The Fisher exact test was performed to compare the
results of in vivo ultrasound clot disruption rate with and
without DDFP; p ,0.05 was considered statistically significant.
Results
In vitro study. Effect of low frequency ultrasound exposure
on clot disruption. The percent clot weight reductions in saline
were 10 6 6% after 3 min of incubation without ultrasound
and 72 6 18% after 3 min of ultrasound exposure at 24.8 kHz,
as shown in Figure 1. Clot weight reductions were significantly
(p , 0.01) greater after ultrasound exposures.
Effect of microbubbles (echo contrast agent) on ultrasound
clot disruption. Additional effects of the echo contrast agent
DDFP on ultrasound clot disruption are shown in Figure 1.
Without ultrasound exposure, the clots lost 10 6 6% of their
weight during 3 min of incubation in saline. DDFP did not
enhance clot weight reduction (7 6 5%) over saline control
after 3 min of incubation without ultrasound.
After 3 min of ultrasound exposure, DDFP significantly
(p , 0.01) accelerated clot weight reduction from 72 6 18% in
saline to 98 6 4%, a nearly complete disruption of whole clots
with a mean weight of 490 mg.
Particulate size after ultrasound clot disruption. The average
diameter of clot debris after 3 min of ultrasound exposure was
3.3 mm (range 2.8 to 3.8) in saline and 3.6 mm (range 3.0 to 4.2)
in DDFP emulsion. These particulate sizes are smaller than
those of red blood cells.
In vivo study. Angiographic results. Angiography con-
firmed that all 34 iliofemoral arteries of 17 rabbits (11 in
protocol 1, 6 in protocol 2) were occluded (TIMI grade 0 flow).
In protocol 1, as shown in Figure 2 and Table 1, of the 11
iliofemoral arteries exposed to ultrasound alone without
DDFP, only 1 (9%) was recanalized with TIMI grade 2 flow
after 45 min of intervention. The other 10 arteries remained
occluded after 60 min of the treatment phase. In contrast, of
the 11 iliofemoral arteries treated by combination of transcu-
taneous ultrasound and DDFP, TIMI grade 3 flow was
achieved in 7 (64%), TIMI grade 2 flow in 1 (9%) and TIMI
grade 1 flow in 1 (9%). TIMI grade 3 flow was accomplished in
three arteries after 15 min, in two arteries after 45 min and in
two arteries after 60 min of intervention. TIMI grade 2 and 1
flow was attained after 30 and 60 min of intervention, respec-
tively. As shown in Table 1, TIMI grade 3 flow, more than
TIMI grade 2 and 1 flow, was achieved with significantly higher
frequency (64% vs. 0%, p 5 0.0039; 73% vs. 9%, p 5 0.0075;
82% vs. 9%, p 5 0.0019, respectively) in the iliofemoral
arteries treated by combination of transcutaneous ultrasound
and DDFP than in those treated by ultrasound alone.
In protocol 2, as shown in Figure 3 and Table 1, no artery
was recanalized at the end of the protocol among six occluded
Figure 1. Effect of low frequency ultrasound, DDFP and combination
of ultrasound and DDFP on percent reduction of clot weight. Clot
weight reductions were significantly (p , 0.01) greater after low
frequency ultrasound exposures than control without ultrasound.
DDFP did not enhance clot weight reduction without ultrasound.
However, DDFP combined with low frequency ultrasound significantly
(p , 0.01) accelerated clot weight reduction from 72 6 18% in saline
to 98 6 4%. *p , 0.01 versus no ultrasound with corresponding
solution.
Figure 2. TIMI flow grade of arteries treated by ultrasound exposure
and DDFP administration (top) and by ultrasound alone (bottom). Of
the 11 iliofemoral arteries treated by combination of transcutaneous
ultrasound and DDFP, 9 were recanalized (TIMI grade 3 flow [open
bars] in 7, TIMI grade 2 flow [hatched bars] in 1, TIMI grade 1 flow
in 1 [crosshatched bar]). Only one artery was recanalized with TIMI
grade 2 flow after ultrasound exposure alone. Solid bars 5 TIMI grade
0 flow; striped bar 5 postintervention period.
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arteries treated only by DDFP administration. Among six
occluded arteries treated by combination of transcutaneous
ultrasound and DDFP, four (67%) were recanalized with TIMI
grade 3 flow, one (17%) with TIMI grade 2 flow, and only a
single artery remained occluded. TIMI grade 3 flow was
achieved after 15 min of intervention in one artery, after
45 min of intervention in two arteries and after 60 min of
intervention in one artery, and TIMI grade 2 flow was attained
after 60 min of intervention. The frequency of TIMI grade 3
flow was not statistically different (67% vs. 0%, p 5 0.0606)
between the two groups. Greater than or equal to TIMI grade
2 flow was achieved with significantly higher frequency (83%
vs. 0%, p 5 0.0152) in the iliofemoral arteries treated by
combination of transcutaneous ultrasound and DDFP than in
those treated by DDFP only.
Figure 4 (A and C) show examples of bilateral rabbit
iliofemoral thrombotic occlusions after electrical induction.
The left iliofemoral artery treated with ultrasound and DDFP
is widely patent (Fig. 4B), whereas the contralateral artery
treated with ultrasound alone remains occluded (Fig. 4D).
When data from protocols 1 and 2 were combined, as shown in
Table 1, recanalization of thrombotically occluded iliofemoral
arteries was not achieved even in a single artery by adminis-
tration of DDFP alone, was successful in 1 (9%) of 11 arteries
(TIMI grade 2 flow) treated by ultrasound alone and was
accomplished in 14 (82%) of 17 arteries (11 with TIMI grade
3 flow, 2 with TIMI grade 2 flow, 1 with TIMI grade 1 flow)
treated by ultrasound and DDFP combined.
In both protocols 1 and 2, no angiographic reocclusion was
detected with serial angiographic monitoring 15 and 30 min
after termination of the intervention. Moreover, no distal or
side branch embolization was observed after successful arterial
recanalization.
Tissue temperature. Tissue temperature of the soft tissue
around the occluded artery was 30.0 6 0.3°C before and did
not change at 5 min, but increased up to 42.6 6 0.9°C at 10 min
of ultrasound exposure without cooling procedures. Skin tem-
perature rose to 63.8 6 2.9°C at 5 min and up to 73.3 6 4.7°C
at 10 min of ultrasound treatment.
Histopathologic results. Figure 5A shows a patent vessel
with only minimal focal residual mural thrombus after ultra-
sound and DDFP exposure. Figure 5B is an example of a
thrombotic occlusion in an iliofemoral artery that received
ultrasound but not DDFP. The 10 arteries that were patent by
angiography were also patent by microscopy. In these patent
arteries, four had no thrombus, two had mild mural residual
thrombus, three had 10% to 20% residual thrombus, and one
had ,50% residual thrombus. Mild focal necrosis of the vessel
wall was noted in four arteries. More severe histopathologic
changes were found in thrombotically occluded arteries (25%
to 50% of vessel wall necrosis with mural thrombus), presum-
ably because of longer duration of ultrasound exposure. The
rabbit dermis as well as subcutaneous soft tissue at the site of
ultrasound exposure revealed thermal damage characterized
by coagulation of the tissue (necrosis) with focal hemorrhage.
Discussion
This study demonstrates that the clot-disrupting effect of
transcutaneous ultrasound was significantly enhanced by
DDFP microbubbles in both in vitro and in vivo experiments
Figure 3. TIMI flow grade of arteries treated by ultrasound exposure
and DDFP administration (top) and by DDFP administration alone
(bottom). Of the six iliofemoral arteries treated by combination of
transcutaneous ultrasound and DDFP, five were recanalized (TIMI
grade 3 flow in four, TIMI grade 2 flow in one). No artery was
recanalized after DDFP administration alone. Symbols as in Figure 1.
Table 1. Frequency of Thrombolysis in Myocardial Infarction Grade
3, 2 and 1 Flow Achieved in Protocols 1 and 2











3 0/11 (0%) 7/11 (64%) 0.0039
$2 1/11 (9%) 8/11 (73%) 0.0075
$1 1/11 (9%) 9/11 (82%) 0.0019










3 0/6 (0%) 4/6 (67%) 0.0606
$2 0/6 (0%) 5/6 (83%) 0.0152
$1 0/6 (0%) 5/6 (83%) 0.0152













3 0/6 (0%) 0/11 (0%) 11/17 (65%) 0.0003
$2 0/6 (0%) 1/11 (9%) 13/17 (76%) 0.0001
$1 0/6 (0%) 1/11 (9%) 14/17 (82%) , 0.0001
Data presented are number (%) of rabbit arteries. DDFP 5 dodecafluoro-
pentane emulsion; TIMI 5 Thrombolysis in Myocardial Infarction.
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without a thrombolytic agent. The simple combination of
transcutaneous ultrasound and DDFP emulsion has potential
for clinical application in patients with thrombotic arterial
occlusions.
Transcutaneous ultrasound clot disruption without throm-
bolytic agent. There are currently two major areas of research
in ultrasound clot disruption: catheter-delivered high intensity,
low frequency (17.5 to 27.5 kHz) ultrasound without concom-
itant use of a thrombolytic agent (9–17) and external (remote)
exposure of higher frequency (170 kHz to 3.4 MHz) ultrasound
in combination with a thrombolytic agent (18–25,27,28).
Catheter-delivered ultrasound was successful in dissolving
clots in vitro (9–15), in vivo in animal models (12,14,16) and in
humans (16,17) without concomitant use of thrombolytic
agents. In contrast, most of the external ultrasound clot
dissolution studies have been performed using ultrasound at
higher frequencies (170 kHz to 3.4 MHz) and have demon-
strated enhancement of drug-induced fibrinolysis in vitro (18–
25,27,39) and in vivo in animal models (19,28–30). Only three
in vitro studies (26,27,31) reported the efficacy of low fre-
quency (20 and 26 kHz) ultrasound clot disruption without a
thrombolytic agent. Our in vitro data in the present study
confirm the results of these reports showing significantly
greater reduction in clot weight after ultrasound exposures at
24.8 kHz compared with the control sample without ultrasound
exposure. Furthermore, in vitro the clot-disrupting effect of
ultrasound was markedly enhanced by DDFP. In the in vivo
portion of our study, transcutaneous ultrasound alone was able
to recanalize only 1 of 11 thrombotically occluded arteries. The
discrepancy between our in vitro and in vivo studies might be
due to the difference in ultrasound intensity at the site of
thrombus. In the in vivo study, the ultrasound intensity might
have declined to a lower level that was not sufficient to disrupt
thrombus by itself. However, when combined with DDFP
administration, transcutaneous ultrasound recanalized oc-
cluded rabbit iliofemoral arteries with TIMI grade 3 flow with
a significantly higher frequency (0 of 11 vs. 7 of 11, p 5 0.0039).
Mechanism of external (transcutaneous) low frequency
ultrasound clot disruption and effect of echo contrast agents.
The predominant mechanism of external (transcutaneous) low
frequency ultrasound clot disruption is believed to be acoustic
cavitation (unstable or transient cavitation) and precavitation
(stable cavitation) as well as the contribution of microstream-
ing and microcurrents generated under an acoustic pressure
field (9,10,13–15,19–21,26–32). Cavitation (unstable or tran-
sient cavitation) is the formation and collapse of microscopic
bubbles when ultrasound waves pass through a liquid with an
alternating pressure. These bubbles, or cavities, take some
cycles to grow and then collapse violently at the point called
resonant size, which is larger at lower frequencies. The collapse
of larger bubbles generates more energy than smaller bubbles.
Precavitation (stable cavitation) is the oscillation or vibration of
microbubbles present or formed in the acoustic field. It
generates large shock waves and also causes microstreaming of
the liquid. If microbubbles of DDFP already exist around the
clot, it can be assumed that they will oscillate and vibrate as
well as grow and collapse, generating high energy and causing
clot disruption.
Tachibana and Tachibana (39) demonstrated enhancement
of the thrombolytic effect of urokinase by initial treatment
Figure 4. Angiographic example in which the left
iliofemoral artery was treated by transcutaneous
ultrasound and DDFP. A and C, Baseline angio-
graphic thrombotic occlusions of both iliofemoral
arteries. B, Angiogram of the widely patent left
iliofemoral artery after 30 min of treatment with
transcutaneous ultrasound and DDFP. D, Angio-
gram of the occluded right iliofemoral artery,
which received 60 min of treatment with ultrasound
alone.
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using sonicated human serum albumin microbubbles and ul-
trasound. However, the experimental setting is different from
our in vitro studies; ultrasound at a frequency of 170 kHz was
irradiated in pulsed mode for 3 min with continuously infused
sonicated human serum albumin microbubbles at the begin-
ning of the study, and the thrombolytic effect of urokinase was
examined for 30 to 120 min. Recently Porter et al. (27)
reported that a 20-kHz, 1.5-W/cm2 ultrasound system and
perfluorocarbon-exposed sonicated dextrose albumin, which is
also an echo contrast agent, resulted in enhanced ultrasound
clot disruption, from 24% with ultrasound alone to 43%.
Although the agent, perfluorocarbon-exposed sonicated dex-
trose albumin, is different from DDFP, these findings are
similar to our in vitro studies.
Clinical significance. This in vitro and in vivo study sug-
gests the possibility for nonpharmacologic clot disruption in
patients with peripheral and coronary arterial thrombotic
occlusions using transcutaneous exposure of ultrasound energy
in combination with DDFP administration. This technique
might also enhance drug-induced fibrinolysis (although this
hypothesis was not tested in the present study), resulting in
more effective and rapid thrombolysis or reduction of hemor-
rhagic complications by a decreased dosage of thrombolytic
agent needed.
Study limitations. A number of limitations have to be
overcome before clinical application of this technique. Trans-
cutaneous application of high intensity, low frequency ultra-
sound was associated with a varied extent of injury to the rabbit
skin and subcutaneous tissue. This side effect is probably
caused by direct thermal effect of ultrasound, indirect thermal
effect through the ultrasound transducer and partially by
cavitation of ultrasound gel placed between the transducer and
the skin. To reduce this complication of ultrasound, some
appropriate cooling system might be needed. Another possi-
bility is to decrease the intensity or increase the frequency of
ultrasound or establish some method to enhance the clot-
disrupting effect of ultrasound (e.g., the combination of a
thrombolytic agent and DDFP). The application method of
ultrasound (attachment of transducer to the skin through
ultrasound gel) might also need modification.
In the clinical setting, there is a substantial distance be-
tween the clot and ultrasound probe due to the intervening
tissue compared with the experimental setting using a rabbit
model. The intensity of ultrasound energy might not be enough
to disrupt the clot in that situation. To apply ultrasound energy
noninvasively, the exact location of the clot will have to be
identified by ultrasound or other technique. In our experiment,
DDFP was directly injected into the iliac artery. However, it
might be very difficult to concentrate a sufficient amount of
DDFP microbubbles around thrombi by intravenous injec-
tion without catheterization. To accomplish this, a tissue
(thrombus)-targeted contrast agent, as reported by Lanza et al.
(40), might be worth utilizing. DDFP is reported to cause
negative hemodynamic effects in canine models (35); however,
this unfavorable effect has not been reported to be significant
in monkeys (37) and humans (38). Another potential side
effect of ultrasound irradiation is the activation of platelets
(41), which might cause reocclusion of the artery. In a rabbit
model, it was reported (29) that ultrasound at 1 MHz and 6.3
W/cm2 significantly shortened the time to initial reflow but was
associated with worse overall arterial patency and more fre-
quent arterial reocclusion after initial recanalization. However,
in our study, no reocclusion of the recanalized artery was
observed at 30 min, and in a canine model, ultrasound at 200
kHz and 0.25 W was reported (42) to be useful for the
prevention of reocclusion after successful thrombolysis of the
femoral arteries by recombinant tissue-type plasminogen acti-
vator. Moreover, in human trials of ultrasound angioplasty
using a frequency of 20 kHz, there has been no evidence to
suggest a prothrombotic effect in peripheral or coronary
Figure 5. Histologic sections of rabbit iliofemoral arteries. A, Rabbit
iliofemoral artery that was angiographically patent after 30 min of
treatment with transcutaneous ultrasound and DDFP; the artery is
patent and without evidence of wall damage. B, Thrombotic occlusion
of a control iliofemoral artery not receiving DDFP. Hemotoxylin-eosin
stain. 310, reduced by 26%.
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arteries; rather, effective thrombus disruption has been seen
(17,43–45).
Conclusions. This study demonstrates that low frequency
ultrasound dissolves a substantial amount of clot without a
thrombolytic agent in vitro, and DDFP microbubbles markedly
enhance ultrasound clot disruption. In the in vivo rabbit
iliofemoral thrombotic occlusion model, arterial recanalization
was accomplished significantly (p , 0.01) more often with the
combination of transcutaneous ultrasound and DDFP emul-
sion than by transcutaneous ultrasound alone or DDFP emul-
sion alone. These findings suggest that the simple combination
of transcutaneous ultrasound and DDFP emulsion without a
thrombolytic agent has potential for clinical application in
patients with thrombotic arterial occlusions.
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